FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 657 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective January 30, 2024 7 ways we’ve influenced progress in lung cancer November 1, 2022 seven Interesting Facts about Malignant tumors Boy Between the sheets July 20, 2023 Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or... February 19, 2026 Load more HOT NEWS Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR... EMA Recommends Extension of Therapeutic Indications for Epcoritamab Acing it: The ambitious early career researchers driving progress in cancer...
